Symcel has announced the appointment of two new highly experienced board members; Erik Walldén and Stefan Löfås. Both will play a key role in bolstering the full execution of the company’s corporate strategy to grow business in the research market and develop much needed solutions for clinical diagnostics. Erik Walldén, who is internationally recognised for his success in building prosperous life science companies and driving business in the medical technology sector, will play a pivotal role in the implementation of the company’s business, sales and marketing strategies and help it develop a larger international network of contacts and prospects. Stefan’s strong scientific expertise, together with vast experience in the valuation and acquisition of companies, will be put to use in strategically assessing life science companies that Symcel should partner with. He will also utilise his solid network within cell analysis and pharmaceutical drug development for business development to aid the company in its growth drive. Moreover, Stefan will in part focus on Symcel’s unique technological offering – putting his extensive scientific and industrial R&D experience to effective use.